This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutAboutBroad CoverageIndicationsEfficacyEfficacyEfficacyLimited Treatment OptionsSafetySafetySafetyDosingDosingAdult DosingPaediatric Dosing
Limited Treatment Options

Robust RWE supports the use of ZAVICEFTA (ceftazidime–avibactam) when treatment options are limited, as shown in more than 4321 patients1–11,12–33*

ZAVICEFTA (ceftazidime-avibactam) suggested a trend towards…
  • Lower 30-day mortality compared with other treatment regimens6
     
  • Lower all-cause 30-day mortality compared with colistin2
ZAVICEFTA demonstrated a trend towards promising…
  • Clinical results for severe infections caused by OXA-48-producing Enterobacterales3
     
  • Clinical results for carbapenem resistant Enterobacterales or P. aeruginosa4
*Limitations of real-world data analyses: the results from non-randomised real-world data analyses are limited by potential selection bias and unknown confounding factors. Pfizer has data on combination therapy of ZAVICEFTA along with metronidazole, aminoglycosides, vancomycin and linezolid based only on Phase III trials and in vitro studies. Beyond this, Pfizer has no data to recommend combination therapy.Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion)

Zyvox ® (linezolid)

Zyvox® (Linezolid) Zyvox 2mg/ml solution for infusion

Abbreviations:OXA, oxacillinase; P. aeruginosa, Pseudomonas aeruginosa; RWE, Real World Evidence.
References:
Castón JJ, et al. Int J Infect Dis 2017;59:118–23.van Duin D, et al. Clin Infect Dis 2018;66:163–71.Sousa A, et al. J Antimicrob Chemother 2018;73:3170–5.Temkin E, et al. Antimicrob Agents Chemother 2017;61:e01964-16.Shields RK, et al. Antimicrob Agents Chemother 2017;61:e00883-17.Tumbarello M, et al. Clin Infect Dis 2019;68:355–64.Tumbarello M, et al. Clin Infect Dis 2021;10.1093/cid/ciab176.Tsolaki V, et al. Antimicrob Agents Chemother 2020;64:e02320-19.Rathish B, et al. Cureus 2021;13:e13081.Atkin SD, et al. Infect Drug Resist 2018;11:1499–510.Chen W, et al. Ann Transl Med 2020;8:39.Aitken SL, et al. Clin Infect Dis 2016;63:954–8.Shields RK, et al. Clin Infect Dis 2016;63:1615–8.Krapp F, et al. Int J Antimicrob Agents 2017;49:770–3.Santevecchi BA, et al. Int J Antimicrob Agents 2018;51:629–35.Shields RK, et al. Antimicrob Agents Chemother 2018;62:e02497-18.Algwizani A, et al. J Infect Public Health 2018;11:793–5.Rodríguez-Núñez O, et al. J Glob Antimicrob Resist 2018;15:136–9.Katchanov J, et al. PLoS One 2018;13:e0195757.Recio R, et al. Int J Antimicrob Agents 2018;52:172–9.De la Calle C, et al. Int J Antimicrob Agents 2019;53:520–4.Alraddadi BM, et al. BMC Infect Dis 2019;19:772.Spoletini G, et al. J Antimicrob Chemother 2019;74:1425–9.Iannaccone M, et al. J Chemother 2020;32:160–2.King M, et al. Antimicrob Agents Chemother 2017;61:e00449-17.Jorgensen SCJ, et al. Open Forum Infect Dis 2019;6:ofz522.Bassetti M, et al. J Glob Antimicrob Resist 2019;17:109–11.Jorgensen SC, et al. Infect Dis Ther 2020;9:291–304.Ackley R, et al. Antimicrob Agents Chemother 2020;64:e02313-19.Vena A, et al. Antibiotics 2020;9:71. doi:10.3390.Strich JR, et al. Clin Infect Dis 2021;72:611–21.Guimarães T, et al. Antimicrob Agents Chemother 2019;63:pii:e00528-19.Falcone M, et al. Crit Care 2020;24:29–41.Efficacy

Legal Category: S1A

Further information available upon request
PP-ZVA-IRL-0239. December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024